Language

Neurology

Neurology - Research

The MultiCare Neuroscience Center of Washington has been active in the search for new and innovative treatments for many of the devastating neurologic diseases that affect our community. The MultiCare Research Institute has partnered with the MultiCare Neuroscience Center of Washington to provide research opportunities to our community in many areas of neurologic science including:

Multiple Sclerosis

John Huddlestone, MD and the site are nationally recognized for excellence. He has been involved in clinical trials for more then 2 decades. Trials are conducted at South Sound’s only nationally recognized Multiple Sclerosis Center. The site has participated in trials evaluating

  • First oral medications for treatment of MS
  • Monoclonal antibody therapy in MS
  • Novel therapeutics with specific targets in MS
  • Comparison of Disease Modifying Therapies in MS
  • Long-term follow-up trials after Exposure to Investigational Products

Post-Herpetic Neuralgia pain control

Restless Leg Syndrome control of symptoms

Migraine Headache treatment and suppression

Movement Disorders treatment

Epilepsy

Two Board Certified Epileptologists, Laura Hershkowitz, DO and Laura Lynam, MD offer clinical trials to patients with epilepsy.


The Investigators in Neuroscience medicine include:

Laura Hershkowitz, DO, FACN (Principal Investigator)

John Huddlestone, MD, FAAN (Principal Investigator)

Stacy Donlon, MD

Peter Kwon, MD

Laura Lynam, MD,

Traci Ryan, MD

Yu Zhu, MD, PhD

Neurology Studies Accepting Participants

Adult - ACTH-MS Fatigue

Study Number: ACTH-MS Fatigue—The effect of ACTH (Acthar®) on measures of fatigue in patients with relapsing multiple sclerosis.

Study Info

Principal Investigator(s)John Huddlestone, MD

Study Coordinator:  Jarrod Monroe, [email protected], 253-403-7449

Adult - Esteem
Study Number: 109MS401—A multicenter, global, observational study to collect information on safety and to document the drug utilization of Tecfidera™ (Dimethyl Fumarate) when used in routine medical practice in the treatment of multiple sclerosis (ESTEEM) to assess the efficacy and safety of TECFIDERA in the United States.

Study Info

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator:  Jarrod Monroe, [email protected], 253-403-7449
Adult - Sanofi OBS13434
Study Number: OBS13434—A prospective, multi-center, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis.

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator: Tonya Stigger[email protected], 253-403-1208
Adult - Ensemble
Study Number: MA30143—An open-label, single-arm, study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis. 

Study Info

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator: Tonya Stigger[email protected], 253-403-1208
Adult - Colucid Gladiator
Study Number: COL MIG-305—An open-label, long-term, safety study of Lasmidttan (100 mg and 200 mg) in the acute treatment of migraine (GLADIATOR).

Study Info

Principal Investigator(s):  John Huddlestone, MD, FAAN

Study Coordinator: Tonya Stigger, [email protected], 253-403-1208
Adult - Protract Observational Study
Study Number: MS200136_0037—Real world clinical, neurological, tolerability and safety outcomes of patients on Rebif and Tecfidera: a retrospective study.

Study Info

Principal Investigator(s)John Huddlestone, MD, FAAN

Study CoordinatorTonya Stigger, [email protected], 253-403-1208
Adult - Evidera Observational Migraine
Study Number: 20150133—A  prospective observational study to evaluate tolerability and

outcomes of prophylactic therapies in migraine.

Principal Investigator(s)John Huddlestone, MD, FAAN

Study CoordinatorTonya Stigger, [email protected], 253-403-1208
Pediatrics - Pfizer 208469
Study Number: A0081042—A double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of Pregabalin as adjunctive therapy in children one month through < 4 years of age with partial onset seizures.

Study Info

Principal Investigator(s)Stephen Phillips, MD

Study CoordinatorCassidy Canorro, [email protected], 253-403-9348
Pediatrics - Pfizer A0081105
Study Number:

A0081105—A randomized, double-blind, placebo-controlled, parallel group,
multicenter trial of Pregabalin as adjunctive therapy in pediatric and adult subjects with primary generalized tonic-clonic seizures.


Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, [email protected], 253-403-9348
Pediatrics - Pfizer 207748
Study Number: A0081106—A 12-month open-label study to evaluate the safety and tolerability of Pregabalin as adjunctive therapy in pediatric subjects one month to 16 years of age with partial onset seizures and primary generalized tonic-clonic seizures.

Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, [email protected], 253-403-9348
Pediatrics - ZOGENIX 1501

Study Number: ZX008-1501—A multicenter, randomized, double-blind, parallel group, placebo-controlled, trial of two fixed doses of ZX008 (Fenfluramine Hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet Syndrome.

Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, [email protected], 253-403-9348

Pediatrics - ZOGENIX 1503

Study Number: ZX008-1503— An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome.

Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, [email protected], 253-403-9348

Pediatrics - EISAI 311

Study Number: E2007-G000-311—An open-label, multicenter study with an extension phase to evaluate the safety, tolerability and exposure-efficacy relationship of perampanel oral suspension when administered as an adjunctive therapy in pediatric subjects (age 4 to < 12 years) with inadequately controlled partial-onset seizures or primary generalized tonic-clonic seizures. 

Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, [email protected], 253-403-9348

Pediatrics - EISAI 338

Study Number: E2007-G000-338 - A multicenter, double-blind, randomized, placebo-controlled trial with an open-label extension phase of perampanel as adjunctive treatment in subjects at least 2 years of age with inadequately controlled seizures associated with Lennox-Gastaut Syndrome.

Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, [email protected]re.org, 253-403-9348

Pediatrics SEP093-364

Study Number: SEP093-364—An open-label Eslicarbazepine Acetate long-term safety and tolerability study in children and adolescents (4 to 7 years).

Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, [email protected], 253-403-9348